A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy

BACKGROUND & AIMS: NS3/4A protease inhibitors, boceprevir or telaprevir, combined with peginterferon and ribavirin was the standard treatment for HCV genotype 1 and remains the only available direct antiviral drug based therapy in some countries. Efficacy and safety data in liver transplant reci...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hepatol
Main Authors: Burton, James R., O’Leary, Jacqueline G., Verna, Elizabeth C., Saxena, Varun, Dodge, Jennifer L., Stravitz, Richard T., Levitsky, Joshua, Trotter, James F., Everson, Gregory T., Brown, Robert S., Terrault, Norah A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394742/
https://ncbi.nlm.nih.gov/pubmed/24801415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2014.04.037
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados